As a stroke prevention device for patients with atrial fibrillation, the Amplatzer™ Amulet™ Left Atrial Appendage (LAA) Occluder is part of the industry-leading Amplatzer line of structural intervention occluders. The Amulet LAA Occluder is a part of Abbott’s broad structural heart portfolio.
Percutaneous, catheter-based occlusion of the LAA—the therapy provided by the Amplatzer Amulet LAA Occluder—is an increasingly performed procedure aiming to reduce the risk of stroke in patients with nonvalvular atrial fibrillation.1 Current evidence suggests that transcatheter occlusion of the LAA reduces the risk of thromboembolic complications associated with nonvalvular atrial fibrillation.2,3
Reducing Stroke RiskDavid Hildick-Smith, MD, Royal Sussex County Hospital, Brighton, England
“What this therapy [use of the Amplatzer Amulet LAA Occluder] does for the patient is twofold. One, it physically deals with the problem and reduces the risk of stroke very substantially. But more than that, it also offers patients a peace of mind.”
AMPLATZER™ Amulet™ LAA Occluder
MAT-2008374 v1.0 | Item approved for Global OUS use only.
- Landmesser U, Schmidt B, Nielsen-Kudsk JE, et al. Left atrial appendage occlusion with the AMPLATZER Amulet device: periprocedural and early clinical/echocardiographic data from a global prospective observational study. EuroIntervention. 2017;13:867-876.
- Hildick-Smith D, Landmesser U, Camm AJ, et al. Left atrial appendage occlusion with the Amplatzer™ Amulet™ device: full results of the prospective global observational study. Euro Heart J. 2020;41:2894–2901. doi:10.1093/eurheartj/ehaa169
- Tarantini G, D’Amico G, Schmidt B, et al. The Impact of CHA2DS2-VASc and HAS-BLED Scores on Clinical Outcomes in the Amplatzer Amulet Study. JACC: Cardiovascular Interventions. 2020;13(18)2099-2108.